Pharmacokinetic/pharmacodynamic model-guided identification of hypoxia-selective 1,2,4-benzotriazine 1,4-dioxides with antitumor activity: The role of extravascular transport

Journal of Medicinal Chemistry

Volumn 50, Issue 25, 2007, Pages 6392-6404

  Hay, Michael P ^a   Hicks, Kevin O ^a   Pruijn, Frederik B ^a   Pchalek, Karin ^a,b   Siim, Bronwyn G ^a,c   Wilson, William R ^a   Denny, William A ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

^b BOEHRINGER INGELHEIM PHARMA GMBH AND CO KG   (Germany)

^c Magdalen Centre   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,4 BENZOTRIAZINE 1,4 DIOXIDE; N 1 (6 ETHOXY 1,4 DIOXIDO 1,2,4 BENZOTRIAZIN 3 YL)N 2 ,N 2 DIMETHYL 1,2 ETHANEDIAMINE; TIRAPAZAMINE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CELL KILLING; CONCENTRATION RESPONSE; CONTROLLED STUDY; CYTOTOXICITY; DRUG PENETRATION; DRUG SCREENING; DRUG SOLUBILITY; DRUG STRUCTURE; DRUG SYNTHESIS; DRUG TRANSPORT; HUMAN; HUMAN CELL; HYPOXIC CELL; IN VIVO STUDY; LIPOPHILICITY; MAXIMUM TOLERATED DOSE; MOUSE; NONHUMAN; XENOGRAFT;

ALGORITHMS; ANIMALS; BIOLOGICAL TRANSPORT; CELL HYPOXIA; CELL LINE, TUMOR; HUMANS; MICE; MICE, NUDE; MODELS, BIOLOGICAL; NEOPLASM TRANSPLANTATION; NEOPLASMS; TRANSPLANTATION, HETEROLOGOUS; TRIAZINES;

EID: 37049004569     PISSN: 00222623     EISSN: None     Source Type: Journal    
DOI: 10.1021/jm070670g     Document Type: Article

References (59)

1. Nordsmark, M.; Overgaard, M.; Overgaard, J. Pretreatment oxygenation predicts radiation response in advanced squamous cell carcinoma of the head and neck. Radiother. Oncol. 1996, 41, 31-39.
2. Fyles, A. W.; Milosevic, M.; Wong, R.; Kavanagh, M. C.; Pintilie, M.; Sun, A.; Chapman, W.; Levin, W.; Manchul, L.; Keane, T. J.; Hill, R. P. Oxygenation predicts radiation response and survival in patients with cervix cancer. Radiother. Oncol. 1998, 48, 149-156.
3. Koukourakis, M. I.; Bentzen, S. M.; Giatromanolaki, A.; Wilson, G. D.; Daley, F. M.; Saunders, M. I.; Dische, S.; Sivridis, E.; Harris, A. L. Endogenous markers of two separate hypoxia response pathways (hypoxia inducible factor 2 α and carbonic anhydrase 9) are associated with radiotherapy failure in head and neck cancer patients recruited in the CHART randomized trial. J. Clin. Oncol. 2006, 24, 727-735.
4. Durand, R. E. The influence of microenvironmental factors during cancer therapy. In Vivo 1994, 8, 691-735.
5. Tannock, I. F. Conventional cancer therapy: Promise broken or promise delayed. Lancet 1998, 351 (Suppl 2), 9-16.
6. Brown, J. M.; Wilson, W. R. Exploiting tumor hypoxia in cancer treatment. Nat. Rev. Cancer 2004, 4, 437-447.
7. Harris, A. L. Hypoxia - A key regulatory factor in tumour growth. Nat. Rev. Cancer 2002, 2, 38-47.
8. Semenza, G. L. HIF-1 and tumor progression: Pathophysiology and therapeutics. Trends Mol. Med. 2002, 8, S62-S67.
9. Pennachietti, S.; Michieli, P.; Galluzzo, M.; Mazzone, M.; Giordano, S.; Comoglio, P. M. Hypoxia promotes invasive growth by transcriptional activation of the met protooncogene. Cancer Cell 2003, 3, 347-361.
10. Cairns, R. A.; Hill, R. P. Acute hypoxia enhances spontaneous lymph node metastasis in an orthotopic murine model of human cervical carcinoma. Cancer Res. 2004, 64, 2054-2061.
11. Subarsky, P.; Hill, R. P. The hypoxic tumour microenvironment and metastatic progression. Clin. Exp. Metastasis 2003, 20, 237-250.
12. Brown, J. M.; Giaccia, A. J. The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res. 1998, 58, 1408-1416.
13. Denny, W. A.; Wilson, W. R.; Hay, M. P. Recent developments in the design of bioreductive drugs. Br. J. Cancer 1996, 74, S32-S38.
14. Brown, J. M. SR 4233 (tirapazamine): A new anticancer drug exploiting hypoxia in solid tumours. Br. J. Cancer 1993, 67, 1163-1170.
15. Denny, W. A.; Wilson, W. R. Tirapazamine: A bioreductive anticancer drug that exploits tumour hypoxia. Expert Opin. Invest. Drugs 2000, 9, 2889-2901.
16. Peters, L. J.; Rischin, D.; Hicks, R. J.; Hughes, P. G.; Sizeland, A. M. Extraordinary tumor control in phase I trial of concurrent tirapazamine cisplatin and radiotherapy for far advanced head and neck cancer. Int. J. Radiat. Oncol., Biol., Phys. 1999, 45, 148-149.
17. Rishin, D.; Peters, L.; Hicks, R.; Hughes, P.; Fisher, R.; Hart, R.; Sexton, M.; D'Costa, I.; von Roemeling, R. Phase I trial of concurrent tirapazamine, cisplatin, and radiotherapy in patients with advanced head and neck cancer. J. Clin. Oncol. 2001, 19, 535-542.
18. Rischin, D.; Peters, L.; Fisher, R.; Macann, A.; Denham, J.; Poulsen, M.; Jackson, M.; Kenny, L.; Penniment, M.; Corry, J.; Lamb, D.; McClure, B. Tirapazamine, cisplatin, and radiation versus fluorouracil, cisplatin, and radiation in patients with locally advanced head and neck cancer: A randomized phase II trial of the Trans-Tasman Radiation Oncology Group (TROG 98.02). J. Clin. Oncol. 2005, 23, 79-87.
19. Le, Q.-T.; Taira, A.; Budenz, S.; Dorie, M. J.; Goffinet, D. R.; Fee, W. E.; Goode, R.; Bloch, D.; Koong, A.; Brown, J. M.; Pinto, H. A. Mature results from a randomized phase II trial of cisplatin plus 5-fluouracil and radiotherapy with or without tirapazamine in patients with respectable stage IV head and neck squamous cell carcinomas. Cancer 2006, 106, 1940-1949.
20. 18F]-misonidazole positron emission tomography-detected tumor hypoxia in patients with advanced head and neck cancer randomly assigned to chemoradiation with or without tirapazamine: a substudy of Trans-Tasman Radiation Oncology Group study 98.02. J. Clin. Oncol. 2006, 24, 2098-2104.
21. Patterson, A. V.; Saunders, M. P.; Chinje, E. C.; Patterson, L. H.; Stratford, I. J. Enzymology of tirapazamine metabolism: A review. Anti-Cancer Drug Des. 1998, 13, 541-573.
22. Baker, M. A.; Zeman, E. M.; Hirst, V. K.; Brown, J. M. Metabolism of SR 4233 by Chinese hamster ovary cells: Basis of selective hypoxic cytotoxicity. Cancer Res. 1988, 48, 5947-5952.
23. Priyadarsini, K. I.; Tracy, M.; Wardman, P. The one electron reduction potential of 3-amino-1,2,4-benzotriazine 1,4-dioxide (Tirapazamine): A hypoxia-selective bioreductive drug. Free Radical Res. 1996, 25, 393-399.
24. Daniels, J. S.; Gates, K. S. DNA cleavage by the antitumor agent 3-amino-1,2,4-benzotriazine 1,4-dioxide (SR4233). Evidence for involvement of hydroxyl radical. J. Am. Chem. Soc. 1996, 118, 3380-3385.
25. Anderson, R. F.; Shinde, S. S.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Activation of 3-amino-1,2,4-benzotriazine 1,4-dioxide antitumor agents to oxidizing species following their one-electron reduction. J. Am. Chem. Soc. 2003, 125, 748-756.
26. Shinde, S. S.; Anderson, R. F.; Hay, M. P.; Gamage, S. A.; Denny, W. A. Oxidation of 2-deoxyribose by benzotriazinyl radicals of antitumor 3-amino-1,2,4-benzotriazine 1,4-dioxides. J. Am. Chem. Soc. 2004, 126, 7853-7864.
27. Jones, G. D. D.; Weinfeld, M. Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res. 1996, 56, 1584-1590.
28. Siim, B. G.; van Zijl, P. L.; Brown, J. M. Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br. J. Cancer 1996, 73, 952-960.
29. Siim, B. G.; Menke, D. R.; Dorie, M. J.; Brown, J. M. Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia. Cancer Res. 1997, 57, 2922-2928.
30. Daniels, J. S.; Gates, K. S.; Tronche, C.; Greenberg, M. M. Direct evidence for bimodal DNA damage induced by tirapazamine. Chem. Res. Toxicol. 1998, 11, 1254-1257.
31. Hwang, J.-T.; Greenberg, M. M.; Fuchs, T.; Gates, K. S. Reaction of the hypoxia-selective antitumor agent tirapazamine with a C1′-radical in single-stranded and double-stranded DNA: The drug and its metabolites can serve as surrogates for molecular oxygen in radical-mediated DNA damage reactions. Biochemistry 1999, 38, 14248-14255.
32. Wang, J.; Biedermann, K. A.; Brown, J. M. Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res. 1992, 52, 4473-4477.
33. Siim, B. G.; Pruijn, F. B.; Sturman, J. R.; Hogg, A.; Hay, M. P.; Brown, J. M.; Wilson, W. R. Selective potentiation of the hypoxic cytotoxicity of tirapazamine by its 1-N-oxide metabolite SR 4317. Cancer Res. 2004, 64, 736-742.
34. Peters, K. B.; Brown, J. M. Tirapazamine: A hypoxia-activated topoisomerase II poison. Cancer Res. 2002, 62, 5248-5283.
35. Doherty, N.; Hancock, S. L.; Kaye, S.; Coleman, C. N.; Shulman, L.; Marquez, C.; Mariscal, C.; Rampling, R.; Senan, S.; Roemeling, R. V. Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int. J. Radiat. Oncol., Biol., Phys. 1994, 29, 379-382.
36. Durand, R. E.; Olive, P. L. Physiologic and cytotoxic effects of tirapazamine in tumor-bearing mice. Radiat. Oncol. Invest. 1997, 5, 213-219.
37. Durand, R. E.; Olive, P. L. Evaluation of bioreductive drugs in multicell spheroids. Int. J. Radiat. Oncol., Biol., Phys. 1992, 22, 689-692.
38. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 641-649.
39. Kyle, A. H.; Minchinton, A. I. Measurement of delivery and metabolism of tirapazamine to tumour tissue using the multilayered cell culture model. Cancer Chemother. Pharmacol. 1999, 43, 213-220.
40. Baguley, B. C.; Hicks, K. O.; Wilson, W. R. Tumour cell cultures in drug development. In Anticancer Drug Development; Baguley, B. C., Kerr, D. J., Eds.; Academic Press: San Diego, CA, 2002; pp 269-284.
41. Hicks, K. O.; Pruijn, F. B.; Sturman, J. R.; Denny, W. A.; Wilson, W. R. Multicellular resistance to tirapazamine is due to restricted extravascular transport: A pharmacokinetic/pharmacodynamic study in multicellular layers. Cancer Res. 2003, 63, 5970-5977.
42. Hicks, K. O.; Siim, B. G.; Pruijn, F. B.; Wilson, W. R. Oxygen dependence of the metabolic activation and cytotoxicity of tirapazamine: Implications for extravascular transport and activity in tumors. Radiat. Res. 2004, 161, 656-666.
43. Hicks, K. O.; Pruijn, F. B.; Secomb, T. W.; Hay, M. P.; Hsu, R.; Brown, J. M.; Denny, W. A.; Dewhirst, M. W.; Wilson, W. R. Use of three-dimensional tissue cultures to model extravascular transport and predict in vivo activity of hypoxia-targeted anticancer drugs. J. Natl. Cancer Inst. 2006, 98, 1118-1128.
44. Hicks, K. O.; Fleming, Y.; Siim, B. G.; Koch, C. J.; Wilson, W. R. Extravascular diffusion of tirapazamine: Effect of metabolic consumption assessed using the multicellular layer model. Int. J. Radiat. Oncol., Biol., Phys. 1998, 42, 641-649.
45. Pruijn, F. B.; Sturman, J.; Liyanage, S.; Hicks, K. O.; Hay, M. P.; Wilson, W. R. Extravascular transport of drugs in tumor tissue: Effect of lipophilicity on diffusion of tirapazamine analogues in multicellular layer cultures. J. Med. Chem. 2005, 48, 1079-1087.
46. Hicks, K. O.; Myint, H.; Patterson, A. V.; Pruijn, F. B.; Siim, B. G.; Patel, K.; Wilson, W. R. Oxygen dependence and extravascular transport of hypoxia-activated prodrugs: comparison of the dinitrobenzamide mustard PR-104A and tirapazamine. Int. J. Radiat. Oncol., Biol., Phys. 2007, 69, 560-571.
47. Kelson, A. B.; McNamara, J. P.; Pandey, A.; Ryan, K. J.; Dorie, M. J.; McAfee, P. A.; Menke, D. R.; Brown, J. M.; Tracy, M. 1,2,4-Benzotriazine 1,4-dioxides. An important class of hypoxic cytotoxins with antitumor activity. Anti-Cancer Drug Des. 1998, 13, 575-592.
48. Hay, M. P.; Gamage, S. A.; Kovacs, M. S.; Pruijn, F. B.; Anderson, R. F.; Patterson, A. V.; Wilson, W. R.; Brown, J. M.; Denny, W. A. Structure-activity relationships of 1,2,4-benzotriazine 1,4-dioxides as hypoxia-selective analogues of tirapazamine. J. Med. Chem. 2003, 46, 169-182.
49. Arndt, F. Ring-closing between nitro and amino groups forming triazines. Ber. 1913, 46, 3522-3529.
50. Siim, B. G.; Hicks, K. O.; Pullen, S. M.; van Zijl, P. L.; Denny, W. A.; Wilson, W. R. Comparison of aromatic and tertiary amine N-oxides of acridine DNA intercalators as bioreductive drugs - Cytotoxicity, DNA binding, cellular uptake, and metabolism. Biochem. Pharmacol. 2000, 60, 969-978.
51. Pruijn, F. B.; Patel, K.; Liyanage, H. D. S.; Hicks, K. O.; Hay, M. P.; Wilson, W. R. Unpublished results.
52. Dedrick, R. L.; Flessner, M. F. Pharmacokinetic problems in peritoneal drug administration: Tissue penetration and surface exposure. J. Natl. Cancer Inst. 1997, 89, 480-487.
53. The computational algorithm is available at http://jnci.oxfordjournals. org/cgi/content/full/98/16/1118/DC1.
54. Cliffe, S.; Taylor, M. L.; Rutland, M.; Baguley, B. C.; Hill, R. P.; Wilson, W. R. Combining bioreductive drugs (SR 4233 or SN 23862) with the vasoactive agents flavone acetic acid or 5,6-dimethylxanthenone acetic acid. Int. J. Radiat. Oncol., Biol., Phys. 1994, 29, 373-377.
55. Mason, J. C.; Tennant, G. Heterocyclic N-oxides. Part VI. Synthesis and nuclear magnetic resonance spectra of 3-aminobenzo-1,2,4-triazines and their mono- and di-N-oxides. J. Chem. Soc. B 1970, 911-916.
56. Hicks, K. O.; Pruijn, F. B.; Baguley, B. C.; Wilson, W. R. Extravascular transport of the DNA intercalator and topoisomerase poison N-[2- (dimethylamino)ethyl]acridine-4-carboxamide (DACA): Diffusion and metabolism in multicellular layers of tumor cells. J. Pharmacol. Exp. Ther. 2001, 297, 1088-1098.
57. Siim, B. G.; Atwell, G. J.; Wilson, W. R. Oxygen dependence of the cytotoxicity and metabolic activation of 4-alkylamino-5-nitroquinoline bioreductive drugs. Br. J. Cancer 1994, 70, 596-603.
58. Skehan, P.; Storeng, R.; Scudiero, D.; Monks, A.; McMahon, J.; Vistica, D.; Warren, J. T.; Bokesch, H.; Kenney, S.; Boyd, M. R. New colorimetric cytotoxicity assay for anticancer-drug screening. J. Natl. Cancer Inst. 1990, 82, 1107-1112.
59. Wilson, W. R.; Pullen, S. M.; Hogg, A.; Hobbs, S. M.; Pruijn, F. B.; Hicks, K. O. In vitro and in vivo models for evaluation of GDEPT: Quantifying bystander killing in cell cultures and tumors. In Suicide Gene Therapy: Methods and Protocols for Cancer; Springer, C. J., Ed.; Humana Press: Totowa, NJ, 2003; pp 403-432.